




Editorial

Chronic Diabetic Complications: Current Challenges and Opportunities

Ilias N. Migdalīs^{1,*}, Leszek Czupryniak², Nebojsa Lalic³, Nikolaos Papanas⁴  and Paul Valensi⁵

¹ Diabetes Centre, Second Department of Internal Medicine, NIMTS Hospital, 11521 Athens, Greece

² Department of Internal Medicine and Diabetology, Medical University of Warsaw, 02-097 Warsaw, Poland; czupniak@vahoo.co.uk

³ Faculty of Medicine, University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases UCC of Serbia, 11000 Belgrade, Serbia; lalic.nm@gmail.com

⁴ Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, 68132 Alexandroupolis, Greece; papanasnikos@yahoo.gr

⁵ Unit of Endocrinology-Diabetology-Nutrition, AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, CINFO, 93140 Bondy, France; paul.valensi@aphp.fr

* Correspondence: ilianmig@otenet.gr

The Special Issue, “Chronic Diabetic Complications: Current Challenges and Opportunities”, is rich in scientific content, covering a wide field of diabetic complications via both original studies and reviews. Psillas et al. [1] discuss the effects of diabetes mellitus, hypercholesterolaemia and hypertension on Bell’s palsy. Migdalīs et al. [2] provide data on agents used to treat hyperglycemia, hypertension and dyslipidemia in subjects with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Margaritidis et al. [3] have shown that Biphasic Insulin Aspart 30 is equally effective to premixed human insulin in controlled subjects with T2DM. Kovářová et al. [4] report that different molecular species of fetuin A influence its variable actions. Further insights into retinopathy and autonomic neuropathy are provided by Hsing et al. [5] and Kempler et al. [6], respectively. In Taiwan, Tai et al. [7] have shown discrepancies between urban and rural areas in terms of diabetic complications. In Italy, Russo et al. [8] have obtained favorable results with edoxaban in patients with atrial fibrillation and diabetes.

Gouveri and Papanas [9] and Penlioglou et al. [10] have revisited olfactory dysfunction and stroke, respectively, in diabetes. Dascalu et al. [11] have conducted a systematic review on diabetic retinopathy following bariatric surgery in T2DM. Baranowska-Jurkun et al. [12] provide an update on microvascular complications in prediabetes. Finally, Koliaki et al. [13] highlight the practical issues and challenges of diabetes management in the COVID-19 era.

Overall, a very satisfactory harvest. Diabetic complications remain a huge challenge [14–16]; we hope that this Special Issue will contribute to their understanding. We also sincerely thank all the authors for their contributions.

Conflicts of Interest: The authors declare no conflict of interest.



Citation: Migdalīs, I.N.; Czupryniak, L.; Lalic, N.; Papanas, N.; Valensi, P. Chronic Diabetic Complications: Current Challenges and Opportunities. *J. Clin. Med.* **2022**, *11*, 673. <https://doi.org/10.3390/jcm11030673>

Received: 11 January 2022

Accepted: 25 January 2022

Published: 28 January 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

References

1. Psillas, G.; Dimas, G.G.; Sarafidou, A.; Didangelos, T.; Perifanis, V.; Kaiafa, G.; Mirkopoulou, D.; Tegos, T.; Savopoulos, C.; Constantinidis, J. Evaluation of effects of diabetes mellitus, hypercholesterolemia and hypertension on Bell's palsy. *J. Clin. Med.* **2021**, *10*, 2357. [[CrossRef](#)]
2. Migdalis, I.N.; Papanas, N.; Ioannidis, I.M.; Sotiropoulos, A.E.; Raptis, A.E.; Dimitriadis, G.D.; on behalf of the Hellenic Diabetic Nephropathy Study HDNS. Antidiabetic and other therapies used in subjects with diabetes and chronic kidney disease in a hospital-based clinic population in Greece. *J. Clin. Med.* **2021**, *10*, 2104. [[CrossRef](#)] [[PubMed](#)]
3. Margaritidis, C.; Karlafti, E.; Kotzakioulafi, E.; Kantartzis, K.; Tziomalos, K.; Kaiafa, G.; Savopoulos, C.; Didangelos, T. Comparison of premixed human insulin 30/70 to biphasic aspart 30 in well-controlled patients with type 2 diabetes using continuous glucose monitoring. *J. Clin. Med.* **2021**, *10*, 1982. [[CrossRef](#)] [[PubMed](#)]
4. Kovářová, M.; Kalbacher, H.; Peter, A.; Häring, H.U.; Didangelos, T.; Stefan, N.; Birkenfeld, A.; Schleicher, E.; Kantartzis, K. Detection and characterization of phosphorylation, glycosylation, and fatty acid bound to fetuin A in human blood. *J. Clin. Med.* **2021**, *10*, 411. [[CrossRef](#)] [[PubMed](#)]
5. Hsing, S.C.; Lee, C.C.; Lin, C.; Chen, J.T.; Chen, Y.H.; Fang, W.H. The severity of diabetic retinopathy is an independent factor for the progression of diabetic nephropathy. *J. Clin. Med.* **2020**, *9*, 3. [[CrossRef](#)] [[PubMed](#)]
6. Kempler, M.; Hajdú, N.; Putz, Z.; Istenes, I.; Vági, O.; Békeffy, M.; Schnabel, K.; Kempler, P.; Körei, A.E. Diabetic cardiovascular autonomic neuropathy, the handgrip test and ambulatory blood pressure monitoring parameters: Are there any diagnostic implications? *J. Clin. Med.* **2020**, *9*, 3322. [[CrossRef](#)] [[PubMed](#)]
7. Tai, S.Y.; He, J.S.; Kuo, C.T.; Kawachi, I. Urban-rural disparities in the incidence of diabetes-related complications in Taiwan: A propensity score matching analysis. *J. Clin. Med.* **2020**, *9*, 3012. [[CrossRef](#)] [[PubMed](#)]
8. Russo, V.; Attena, E.; Rago, A.; Melillo, E.; Di Micco, P.; Papa, A.A.; Napolitano, G.; D'Onofrio, A.; Golino, P.; Nigro, G. Clinical outcome of edoxaban vs. vitamin k antagonists in patients with atrial fibrillation and diabetes mellitus: Results from a multicenter, propensity-matched, real-world cohort study. *J. Clin. Med.* **2020**, *9*, 1621. [[CrossRef](#)] [[PubMed](#)]
9. Gouveri, E.; Papanas, N. Olfactory Dysfunction: A complication of diabetes or a factor that complicates glucose metabolism? A narrative review. *J. Clin. Med.* **2021**, *10*, 5637. [[CrossRef](#)] [[PubMed](#)]
10. Penlioglou, T.; Stoian, A.P.; Papanas, N. Diabetes, vascular aging and stroke: Old dogs, new tricks? *J. Clin. Med.* **2021**, *10*, 4620. [[CrossRef](#)] [[PubMed](#)]
11. Dascalu, A.M.; Stoian, A.P.; Cherecheanu, A.P.; Serban, D.; Costea, D.O.; Tudosie, M.S.; Stana, D.; Tanasescu, D.; Sabau, A.D.; Gangura, G.A.; et al. Outcomes of diabetic retinopathy post-bariatric surgery in patients with type 2 diabetes mellitus. *J. Clin. Med.* **2021**, *10*, 3736. [[CrossRef](#)] [[PubMed](#)]
12. Baranowska-Jurkun, A.; Matuszewski, W.; Bandurska-Stankiewicz, E. Chronic microvascular complications in prediabetic states—an overview. *J. Clin. Med.* **2020**, *9*, 3289. [[CrossRef](#)] [[PubMed](#)]
13. Koliaki, C.; Tentolouris, A.; Eleftheriadou, I.; Melidonis, A.; Dimitriadis, G.; Tentolouris, N. Clinical management of diabetes mellitus in the era of COVID-19: Practical issues, peculiarities and concerns. *J. Clin. Med.* **2020**, *9*, 2288. [[CrossRef](#)] [[PubMed](#)]
14. Migdalis, I.N.; Papanas, N.; Raptis, A.E.; Ioannidis, I.M.; Sotiropoulos, A.E.; Dimitriadis, G.D.; Hellenic Diabetic Nephropathy Study (HDNS) Group. The prevalence of diabetic chronic kidney disease in adult Greek subjects with type 2 diabetes mellitus: A series from hospital-based diabetes clinics. *Diabetes Res. Clin. Pract.* **2020**, *166*, 108243. [[CrossRef](#)] [[PubMed](#)]
15. Bönhof, G.J.; Herder, C.; Ziegler, D. Diagnostic tools, biomarkers, and treatments in diabetic polyneuropathy and cardiovascular autonomic neuropathy. *Curr. Diabetes Rev.* **2021**, *17*, e120421192781. [[CrossRef](#)] [[PubMed](#)]
16. Petrova, N.L.; Donaldson, N.K.; Bates, M.; Tang, W.; Jemmott, T.; Morris, V.; Dew, T.; Meacock, L.; Elias, D.A.; Moniz, C.F.; et al. Effect of recombinant human parathyroid hormone (1–84) on resolution of active Charcot neuro-osteoarthropathy in diabetes: A randomized, double-blind, placebo-controlled study. *Diabetes Care* **2021**, *44*, 1613–1621. [[CrossRef](#)] [[PubMed](#)]